ArticleBMC biotechnology2025
The role of Genipin crosslinked extracellular matrix loaded bFGF in the repair of peripheral nerve injury.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBiomaterials have been extensively utilized in the field of tissue regeneration and repair. The objective of this study was to develop and assess the efficacy of ECM-G@bFGF in the repair of sciatic nerve injuries.
methodsThe extracellular matrix (ECM) of the sciatic nerve was extracted using an acellularization technique. Functionalized ECM-G@bFGF was prepared by cross-linking a mixture of basic fibroblast growth factor (bFGF) and genipin(G) into the ECM scaffold. The physicochemical characteristics, biocompatibility, and sustained-release properties of ECM-G@bFGF were systematically evaluated. Additionally, in vivo experiments were conducted to assess the efficacy of ECM-G@bFGF in promoting peripheral nerve regeneration and repair.
resultsThe results demonstrated that the thread-like spatial structure of the sciatic nerve was preserved within the extracellular matrix (ECM) after decellularization. The mixture of basic fibroblast growth factor (bFGF) and Genipin was evenly distributed throughout the ECM. The ECM-G@bFGF exhibited excellent swelling properties, favorable biocompatibility, and no significant cytotoxicity. Through the cross-linking effect of Genipin, the degradation rate of the ECM was effectively reduced, and the release duration of bFGF was significantly prolonged. In vivo experimental results further indicated that ECM-G@bFGF could promote faster regeneration of nerve axons, mitigate gastrocnemius denervation-induced atrophy, restore sciatic nerve conduction function, and enhance the recovery of hind limb functionality.
conclusionThe experimental results regarding the slow release of growth factors from ECM-G@bFGF demonstrated that ECM derived from different tissues could facilitate the release of growth factors from various sources via Genipin cross-linking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.